ALXO News and Press, ALX Oncology Holdings Inc. From 08/16/22

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- ALX Oncolo...

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ (&...

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 2 investi...

Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...

ALX Oncology press release ( NASDAQ: ALXO ): Q2 GAAP EPS of -$0.81 misses by $0.18 . Cash, cash equivalents and investments as of June 30, 2022 were $324.2 million. For further details see: ALX Oncology GAAP EPS of -$0.81 misses by $0.18

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quar...

The U.S. Food and Drug Administration (FDA) granted fast track designation to ALX Oncology's ( NASDAQ: ALXO ) evorpacept, in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), as a first-line treatment of adult patients with PD-L1 positive advanced he...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to ALX Oncology's ( NASDAQ: ALXO ) evorpacept to treat patients with acute myeloid leukemia (AML). "Receiving orphan drug designation in AML, and previously in gastric cancer, from the FDA...

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...